CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SPPL3 (ImmuneEditome ID:121665)

1. Gene summary of enriched editing regions for SPPL3

check button Gene summary
Gene informationGene symbol

SPPL3

Gene ID

121665

GeneSynonymsIMP2|MDHV1887|PRO4332|PSH1|PSL4
GeneCytomap

12q24.31

GeneTypeprotein-coding
GeneDescriptionsignal peptide peptidase-like 3|SPP-like 3|intramembrane protease 2|presenilin homologous protein 1|presenilin-like protein 4
GeneModificationdate20230517
UniprotIDQ8TCT6;F5H2A2;F5H4L1;F5H4Y6;F5H7J2;F5H6I1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr12:120772004-120772278:-ENST00000353487.5ENSG00000157837.14SPPL3intronicL2c,AluSq2chr12:120772004-120772278:-.alignment
chr12:120772004-120772278:-ENST00000536996.4ENSG00000157837.14SPPL3intronicL2c,AluSq2chr12:120772004-120772278:-.alignment
chr12:120772004-120772278:-ENST00000543608.4ENSG00000157837.14SPPL3intronicL2c,AluSq2chr12:120772004-120772278:-.alignment
chr12:120772004-120772278:-ENST00000543854.4ENSG00000157837.14SPPL3intronicL2c,AluSq2chr12:120772004-120772278:-.alignment
chr12:120802523-120802735:-ENST00000353487.5ENSG00000157837.14SPPL3intronicAluSxchr12:120802523-120802735:-.alignment
chr12:120802523-120802735:-ENST00000536996.4ENSG00000157837.14SPPL3intronicAluSxchr12:120802523-120802735:-.alignment
chr12:120802523-120802735:-ENST00000540091.1ENSG00000157837.14SPPL3intronicAluSxchr12:120802523-120802735:-.alignment
chr12:120802523-120802735:-ENST00000543181.4ENSG00000157837.14SPPL3intronicAluSxchr12:120802523-120802735:-.alignment
chr12:120802523-120802735:-ENST00000543608.4ENSG00000157837.14SPPL3intronicAluSxchr12:120802523-120802735:-.alignment
chr12:120802523-120802735:-ENST00000543854.4ENSG00000157837.14SPPL3intronicAluSxchr12:120802523-120802735:-.alignment
chr12:120808211-120809270:-ENST00000353487.5ENSG00000157837.14SPPL3intronicMIR3,AluY,AluJb,L1ME4cchr12:120808211-120809270:-.alignment
chr12:120808211-120809270:-ENST00000536996.4ENSG00000157837.14SPPL3intronicMIR3,AluY,AluJb,L1ME4cchr12:120808211-120809270:-.alignment
chr12:120808211-120809270:-ENST00000540091.1ENSG00000157837.14SPPL3intronicMIR3,AluY,AluJb,L1ME4cchr12:120808211-120809270:-.alignment
chr12:120808211-120809270:-ENST00000543181.4ENSG00000157837.14SPPL3intronicMIR3,AluY,AluJb,L1ME4cchr12:120808211-120809270:-.alignment
chr12:120808211-120809270:-ENST00000543608.4ENSG00000157837.14SPPL3intronicMIR3,AluY,AluJb,L1ME4cchr12:120808211-120809270:-.alignment
chr12:120808211-120809270:-ENST00000543854.4ENSG00000157837.14SPPL3intronicMIR3,AluY,AluJb,L1ME4cchr12:120808211-120809270:-.alignment
chr12:120863915-120864484:-ENST00000353487.5ENSG00000157837.14SPPL3intronicAluSq2,AluJr4,Charlie1achr12:120863915-120864484:-.alignment
chr12:120863915-120864484:-ENST00000536996.4ENSG00000157837.14SPPL3intronicAluSq2,AluJr4,Charlie1achr12:120863915-120864484:-.alignment
chr12:120863915-120864484:-ENST00000543608.4ENSG00000157837.14SPPL3intronicAluSq2,AluJr4,Charlie1achr12:120863915-120864484:-.alignment
chr12:120863915-120864484:-ENST00000543854.4ENSG00000157837.14SPPL3intronicAluSq2,AluJr4,Charlie1achr12:120863915-120864484:-.alignment
chr12:120868131-120868757:-ENST00000353487.5ENSG00000157837.14SPPL3intronicMER5A,AluSc,AluJbchr12:120868131-120868757:-.alignment
chr12:120868131-120868757:-ENST00000536996.4ENSG00000157837.14SPPL3intronicMER5A,AluSc,AluJbchr12:120868131-120868757:-.alignment
chr12:120868131-120868757:-ENST00000543608.4ENSG00000157837.14SPPL3intronicMER5A,AluSc,AluJbchr12:120868131-120868757:-.alignment
chr12:120868131-120868757:-ENST00000543854.4ENSG00000157837.14SPPL3intronicMER5A,AluSc,AluJbchr12:120868131-120868757:-.alignment


Top

2. Tumor-specific enriched editing regions for SPPL3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000157837.14,SPPL3KIRPCliEAG2.2217e-023.0866e-020.3297image
ENSG00000157837.14,SPPL3LIHCPathEAG1.7854e-021.6841e-03-0.4866image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for SPPL3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for SPPL3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for SPPL3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000157837.14,SPPL3BLCAEAGMast_cells_activated1.6181e-020.2787image
ENSG00000157837.14,SPPL3BRCAEAGPlasma_cells2.2895e-02-0.1260image
ENSG00000157837.14,SPPL3CESCEAGMacrophages_M23.0721e-02-0.2840image
ENSG00000157837.14,SPPL3COADEAGDendritic_cells_activated2.3466e-050.5170image
ENSG00000157837.14,SPPL3ESCAEAGB_cells_naive1.9357e-02-0.2714image
ENSG00000157837.14,SPPL3HNSCEAGNeutrophils2.8695e-020.1919image
ENSG00000157837.14,SPPL3KIRPEAGT_cells_gamma_delta2.1925e-040.4462image
ENSG00000157837.14,SPPL3LAMLEAGT_cells_follicular_helper1.7321e-020.2376image
ENSG00000157837.14,SPPL3LGGEAGNK_cells_resting3.0913e-020.2041image
ENSG00000157837.14,SPPL3LUADEAGT_cells_CD4_memory_activated4.0928e-030.2793image
ENSG00000157837.14,SPPL3LUSCEAGT_cells_CD4_memory_activated1.4545e-020.1757image
ENSG00000157837.14,SPPL3PAADEAGT_cells_follicular_helper1.0640e-070.7273image
ENSG00000157837.14,SPPL3PCPGEAGT_cells_regulatory_(Tregs)2.6049e-020.3656image
ENSG00000157837.14,SPPL3PRADEAGDendritic_cells_resting4.4936e-02-0.1776image
ENSG00000157837.14,SPPL3READEAGT_cells_CD4_memory_resting8.7448e-030.5448image
ENSG00000157837.14,SPPL3SARCEAGT_cells_CD4_memory_activated9.7781e-040.4440image
ENSG00000157837.14,SPPL3SKCMEAGMast_cells_resting3.7633e-02-0.1877image
chr12:120863915-120864484:-STADEERT_cells_CD4_memory_activated2.6302e-020.2304image
chr12:120868131-120868757:-STADEERT_cells_CD4_memory_activated1.5075e-030.5454image
ENSG00000157837.14,SPPL3STADEAGT_cells_regulatory_(Tregs)1.3800e-020.1920image
ENSG00000157837.14,SPPL3THCAEAGPlasma_cells1.3078e-020.2188image
ENSG00000157837.14,SPPL3THYMEAGNK_cells_resting2.5571e-070.8318image


Top

6. Enriched editing regions and immune gene sets for SPPL3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000157837.14,SPPL3BLCAGSVA_HALLMARK_HEME_METABOLISMEAG9.4941e-05-0.4380image
ENSG00000157837.14,SPPL3BRCAGSVA_HALLMARK_HEME_METABOLISMEAG5.0978e-03-0.1548image
ENSG00000157837.14,SPPL3CESCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.5507e-03-0.4063image
ENSG00000157837.14,SPPL3COADGSVA_HALLMARK_DNA_REPAIREAG2.9538e-08-0.6434image
ENSG00000157837.14,SPPL3ESCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG4.7284e-020.2314image
ENSG00000157837.14,SPPL3HNSCGSVA_HALLMARK_E2F_TARGETSEAG1.8002e-02-0.2072image
ENSG00000157837.14,SPPL3KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.6865e-04-0.4533image
ENSG00000157837.14,SPPL3LAMLGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.3528e-02-0.2264image
ENSG00000157837.14,SPPL3LGGGSVA_HALLMARK_UV_RESPONSE_DNEAG1.1322e-02-0.2385image
ENSG00000157837.14,SPPL3LIHCGSVA_HALLMARK_PEROXISOMEEAG4.2097e-020.3043image
ENSG00000157837.14,SPPL3LUADGSVA_HALLMARK_HEME_METABOLISMEAG2.7674e-03-0.2906image
ENSG00000157837.14,SPPL3LUSCGSVA_HALLMARK_SPERMATOGENESISEAG1.9552e-020.1680image
ENSG00000157837.14,SPPL3OVGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.1489e-02-0.3016image
ENSG00000157837.14,SPPL3PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.2326e-05-0.3586image
ENSG00000157837.14,SPPL3READGSVA_HALLMARK_APOPTOSISEAG4.8207e-02-0.4258image
ENSG00000157837.14,SPPL3SARCGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.9980e-020.2858image
ENSG00000157837.14,SPPL3SKCMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG1.2415e-020.2248image
chr12:120868131-120868757:-STADGSVA_HALLMARK_MTORC1_SIGNALINGEER6.8776e-030.4754image
chr12:120863915-120864484:-STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER5.9231e-050.4040image
ENSG00000157837.14,SPPL3STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.0887e-020.1803image
ENSG00000157837.14,SPPL3TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.5190e-02-0.3148image
ENSG00000157837.14,SPPL3THCAGSVA_HALLMARK_GLYCOLYSISEAG3.3717e-020.1879image
ENSG00000157837.14,SPPL3THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.4998e-03-0.5776image
ENSG00000157837.14,SPPL3UCECGSVA_HALLMARK_HEME_METABOLISMEAG4.3371e-03-0.4643image


Top

7. Enriched editing regions and drugs for SPPL3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000157837.14,SPPL3BLCABI.2536EAG5.5560e-050.4508image
ENSG00000157837.14,SPPL3BRCACHIR.99021EAG2.4074e-03-0.1675image
ENSG00000157837.14,SPPL3CESCBMS.708163EAG4.9698e-030.3640image
ENSG00000157837.14,SPPL3COADCCT007093EAG3.2197e-09-0.6754image
ENSG00000157837.14,SPPL3ESCACytarabineEAG1.4122e-03-0.3644image
ENSG00000157837.14,SPPL3HNSCBryostatin.1EAG2.7248e-03-0.2608image
ENSG00000157837.14,SPPL3KIRPAZD6482EAG1.2300e-040.4617image
ENSG00000157837.14,SPPL3LAMLMidostaurinEAG3.7293e-020.2086image
ENSG00000157837.14,SPPL3LGGCCT007093EAG2.1808e-020.2166image
ENSG00000157837.14,SPPL3LIHCGSK.650394EAG4.4464e-020.3011image
ENSG00000157837.14,SPPL3LUADCMKEAG2.1638e-02-0.2250image
ENSG00000157837.14,SPPL3LUSCGefitinibEAG3.3484e-060.3283image
ENSG00000157837.14,SPPL3OVKU.55933EAG1.2277e-03-0.4402image
ENSG00000157837.14,SPPL3PAADAZD6244EAG3.1412e-02-0.3408image
ENSG00000157837.14,SPPL3PRADGNF.2EAG2.9118e-04-0.3175image
ENSG00000157837.14,SPPL3READErlotinibEAG2.5306e-04-0.7044image
ENSG00000157837.14,SPPL3SKCMEHT.1864EAG2.4999e-030.2703image
chr12:120868131-120868757:-STADErlotinibEER7.4492e-04-0.5818image
chr12:120863915-120864484:-STADAZD7762EER8.1416e-03-0.2729image
ENSG00000157837.14,SPPL3STADMethotrexateEAG2.7006e-02-0.1738image
ENSG00000157837.14,SPPL3TGCTCisplatinEAG3.1070e-02-0.3219image
ENSG00000157837.14,SPPL3THCAEmbelinEAG3.1613e-050.3590image
ENSG00000157837.14,SPPL3THYMAZD6244EAG2.5231e-08-0.8645image
ENSG00000157837.14,SPPL3UCECKIN001.135EAG3.4955e-020.3525image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType